FIH TO CLINICAL ACCELERATION CONCURRENT Investor accelerator, what’s of interest during clinical acceleration
Friday, June 2, 2023 09:15 AM - 10:15 AM
Room 242AB
FROM FIH TO CLINICAL ACCELERATION
Concurrent
Chair
Bryan Poltilove, MBA, Operating Partner, BroadOak Capital Partners, USA
Speakers
Julian Hanak, MSc, Chief Executive Officer, Purespring Therapeutics Ltd, UK
Leen (Marleen) Limbourg, MD, MBA, Executive Committee Member, White Fund SA, Belgium
Discussion on the main considerations and observations of investment activity in mid-/late- stage clinical trials. With few late stage assets in/nearing the market, we see a large number of large investments in companies at an early stage of development
Some notably large investments to date have been made largely on the promise of therapeutics addressing their expected patient populations. As more of these products progress and accrue clinical data, are we beginning to see a change in this decision making? This session will look at what companies can do and what data they need to demonstrate to continue to impress investors. In response to some of these large investments, we’re seeing novel strategic models to de-risk the large upfront sums, we will explore some of these pro’s and con’s of these models and when they appropriate to explore for a company.
Bryan Poltilove, MBA, Operating Partner, BroadOak Capital Partners, USA
Speakers
Julian Hanak, MSc, Chief Executive Officer, Purespring Therapeutics Ltd, UK
Leen (Marleen) Limbourg, MD, MBA, Executive Committee Member, White Fund SA, Belgium
Discussion on the main considerations and observations of investment activity in mid-/late- stage clinical trials. With few late stage assets in/nearing the market, we see a large number of large investments in companies at an early stage of development
Some notably large investments to date have been made largely on the promise of therapeutics addressing their expected patient populations. As more of these products progress and accrue clinical data, are we beginning to see a change in this decision making? This session will look at what companies can do and what data they need to demonstrate to continue to impress investors. In response to some of these large investments, we’re seeing novel strategic models to de-risk the large upfront sums, we will explore some of these pro’s and con’s of these models and when they appropriate to explore for a company.
